P238. Comparative outcomes for single-level unilateral biportal endoscopic versus tubular microdiscectomy

Yixuan Tong,Samuel Ezeonu,Yong H. Kim,Charla R. Fischer

DOI: https://doi.org/10.1016/j.spinee.2024.06.361

IF: 4.297

2024-08-20

The Spine Journal

Abstract:BACKGROUND CONTEXT Unilateral Biportal Endoscopic (UBE) microdiscectomy is an emerging minimally invasive surgery (MIS) used to treat symptomatic lumbar disc herniation. This technique involves the use of two same-sided endoscopic channels for enhanced operative visualization and flexibility. UBE is emerging as a less-invasive alternative to tubular microdiscectomy, another established MIS technique. However, there remains limited literature comparing outcomes between the UBE and tubular techniques. PURPOSE To assess surgical outcomes and pain medication consumption between UBE and tubular lumbar microdiscectomy. STUDY DESIGN/SETTING Retrospective cohort study. PATIENT SAMPLE Adult patients undergoing primary, single-level UBE or tubular lumbar microdiscectomy surgery at a single, high-volume academic institution between 2018 and 2023. OUTCOME MEASURES Outcomes of interest include operative time, surgical complications and reoperations, and postoperative consumption of opioid and nonopioid pain medications. METHODS A total of 102 patients—48 in the UBE cohort and 54 in the tubular cohort—were included in the study. Postoperative pain medication consumption was recorded across four time intervals: discharge to 2-week, 2-week to 6-week, 6-week to 3-month, and 3-month to 6-month follow-up. Opioid consumption was converted to morphine milligram equivalents (MME). Standard statistical analyses were performed to assess for differences between the two groups. RESULTS There were no statistically significant differences in patient demographics between cohorts with respect to age, gender, smoking status, Charlson comorbidity index, or American Society of Anesthesia score, with the exception of body mass index (kg/m 2 ) that was lower in the UBE cohort (25.7 UBE vs 28.7 tubular, P = 0.02). Average operative time (minutes) was higher for UBE patients (133.1 vs 86.6, P < 0.001). Operative time in the UBE group trended downward over time, but did not reach statistical significance (P = 0.07). Otherwise, there were no differences in intraoperative or postoperative complications or reoperation rates. Average daily MME significantly decreased over time within both cohorts: UBE patients consumed on average 11.1 MMEs daily from discharge to 2-week follow-up, which decreased to 0 MME at 3- to 6-month follow-up (P < 0.001); similarly, tubular patients' opioid consumption decreased from 14.1 to 0.03 MMEs (P < 0.001). Between the two cohorts, average daily MME was lower from discharge to 2-week follow-up in the UBE group (P = 0.02). However, there were no significant differences thereafter. Commonly prescribed nonopioid medications included acetaminophen, meloxicam, gabapentin, and various muscle relaxants and steroid medications. A smaller proportion of patients in the UBE group were prescribed nonopioid medications at the discharge to 2-week (70.8% vs 92.6%, P = 0.01) and 2-week to 6-week (52.1% vs 85.2%, P < 0.001) follow-up times, with no significant differences thereafter. CONCLUSIONS UBE microdiscectomy is associated with longer operative time. Operative times trended down over time, suggesting a learning curve with the newer UBE technique. There is lower opioid and nonopioid pain medication consumption for UBE patients in the early postoperative period, which may be attributed to the less-invasive nature of the surgery. However, pain medication consumption is comparable thereafter. FDA Device/Drug Status This abstract does not discuss or include any applicable devices or drugs.

clinical neurology,orthopedics